Cumulative defects in DNA repair pathways drive the PARP inhibitor response in high-grade serous epithelial ovarian cancer cell lines

PARP inhibitors (PARPi), such as Olaparib, have shown promising results in high-grade serous (HGS) epithelial ovarian cancer (EOC) treatment. PARPi sensitivity has been mainly associated with homologous recombination (HR) deficiency, but clinical trials have shown that predicting actual patient resp...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Oncotarget
Autori principali: Fleury, Hubert, Carmona, Euridice, Morin, Vincent G., Meunier, Liliane, Masson, Jean-Yves, Tonin, Patricia N., Provencher, Diane, Mes-Masson, Anne-Marie
Natura: Artigo
Lingua:Inglês
Pubblicazione: Impact Journals LLC 2016
Soggetti:
Research Paper
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5522225/
https://ncbi.nlm.nih.gov/pubmed/27374179
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.10308
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi